| IL-23 secreted by myeloid cells drives castration-resistant prostate cancer A Calcinotto, C Spataro, E Zagato, D Di Mitri, V Gil, M Crespo, ... Nature 559 (7714), 363-369, 2018 | 318 | 2018 |
| Re-education of tumor-associated macrophages by CXCR2 blockade drives senescence and tumor inhibition in advanced prostate cancer D Di Mitri, M Mirenda, J Vasilevska, A Calcinotto, N Delaleu, A Revandkar, ... Cell reports 28 (8), 2156-2168. e5, 2019 | 156 | 2019 |
| SPOP-mutated/CHD1-deleted lethal prostate cancer and abiraterone sensitivity G Boysen, DN Rodrigues, P Rescigno, G Seed, D Dolling, R Riisnaes, ... Clinical cancer research 24 (22), 5585-5593, 2018 | 141 | 2018 |
| Targeting the p300/CBP axis in lethal prostate cancer J Welti, A Sharp, N Brooks, W Yuan, C McNair, SN Chand, A Pal, ... Cancer Discovery 11 (5), 1118-1137, 2021 | 138 | 2021 |
| Targeting bromodomain and extra-terminal (BET) family proteins in castration-resistant prostate cancer (CRPC) J Welti, A Sharp, W Yuan, D Dolling, D Nava Rodrigues, I Figueiredo, ... Clinical Cancer Research 24 (13), 3149-3162, 2018 | 132 | 2018 |
| CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair TR Shenoy, G Boysen, MY Wang, QZ Xu, W Guo, FM Koh, C Wang, ... Annals of Oncology 28 (7), 1495-1507, 2017 | 117 | 2017 |
| Single-cell analyses of prostate cancer liquid biopsies acquired by apheresis MB Lambros, G Seed, S Sumanasuriya, V Gil, M Crespo, M Fontes, ... Clinical Cancer Research 24 (22), 5635-5644, 2018 | 109 | 2018 |
| Advanced prostate cancer with ATM loss: PARP and ATR inhibitors A Neeb, N Herranz, S Arce-Gallego, S Miranda, L Buroni, W Yuan, A Athie, ... European urology 79 (2), 200-211, 2021 | 85 | 2021 |
| Selective inhibition of SIN3 corepressor with avermectins as a novel therapeutic strategy in triple-negative breast cancer YJ Kwon, K Petrie, BA Leibovitch, L Zeng, M Mezei, L Howell, V Gil, ... Molecular cancer therapeutics 14 (8), 1824-1836, 2015 | 77 | 2015 |
| Deregulated expression of HDAC9 in B cells promotes development of lymphoproliferative disease and lymphoma in mice VS Gil, G Bhagat, L Howell, J Zhang, CH Kim, S Stengel, F Vega, A Zelent, ... Disease models & mechanisms 9 (12), 1483-1495, 2016 | 49 | 2016 |
| Targeting the SIN3A-PF1 interaction inhibits epithelial to mesenchymal transition and maintenance of a stem cell phenotype in triple negative breast cancer N Bansal, K Petrie, R Christova, CY Chung, BA Leibovitch, L Howell, V Gil, ... Oncotarget 6 (33), 34087, 2015 | 35 | 2015 |
| HER3 is an actionable target in advanced prostate cancer V Gil, S Miranda, R Riisnaes, B Gurel, M D’Ambrosio, A Vasciaveo, ... Cancer research 81 (24), 6207-6218, 2021 | 30 | 2021 |
| CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo A Alajati, M D’Ambrosio, M Troiani, S Mosole, L Pellegrini, J Chen, ... The Journal of clinical investigation 130 (5), 2435-2450, 2020 | 30 | 2020 |
| JMJD6 is a druggable oxygenase that regulates AR-V7 expression in prostate cancer A Paschalis, J Welti, AJ Neeb, W Yuan, I Figueiredo, R Pereira, A Ferreira, ... Cancer research 81 (4), 1087-1100, 2022 | 26 | 2022 |
| CD38 in advanced prostate cancers C Guo, M Crespo, B Gurel, D Dolling, J Rekowski, A Sharp, A Petremolo, ... European urology 79 (6), 736-746, 2021 | 23 | 2021 |
| Molecular and in vivo characterization of cancer-propagating cells derived from MYCN-dependent medulloblastoma Z Ahmad, L Jasnos, V Gil, L Howell, A Hallsworth, K Petrie, T Sawado, ... PloS one 10 (3), e0119834, 2015 | 22 | 2015 |
| Prostate-specific membrane antigen expression and response to DNA damaging agents in prostate cancer B Sheehan, A Neeb, L Buroni, A Paschalis, R Riisnaes, B Gurel, V Gil, ... Clinical Cancer Research 28 (14), 3104-3115, 2022 | 16 | 2022 |
| Inhibition of the PI3K/AKT/mTOR pathway leads to down-regulation of c-Myc and overcomes resistance to ATRA in acute myeloid leukemia RT Swords, T Schenk, S Stengel, VS Gil, KR Petrie, A Perez, R Ana, ... Blood 126 (23), 1363, 2015 | 16 | 2015 |
| Suppression of MYC by PI3K/AKT/mTOR pathway inhibition in combination with all‐trans retinoic acid treatment for therapeutic gain in acute myeloid leukaemia S Stengel, KR Petrie, Y Sbirkov, C Stanko, F Ghazvini Zadegan, V Gil, ... British Journal of Haematology 198 (2), 338-348, 2022 | 13 | 2022 |
| Immune biomarkers in metastatic castration-resistant prostate cancer MDF de la Maza, K Chandran, J Rekowski, IM Shui, B Gurel, E Cross, ... European Urology Oncology 5 (6), 659-667, 2022 | 11 | 2022 |
